Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals has announced the Japan Patent Office (JPO) has granted a second patent for RECCE antibiotics
  • The second patent includes the lead compound, RECCE 327, which is an antibiotic for treating blood infections and sepsis
  • This provides Recce with intellectual property protection until November 2035
  • Japan is the second largest pharmaceutical market in the world
  • Patents have also been granted by Europe and the U.S. patent offices earlier this year

Recce Pharmaceuticals has been granted a second patent for its RECCE antibiotics by the Japan Patent Office (JPO).

The second patent includes the lead compound, RECCE 327. This antibiotic has been developed to treat blood infections and sepsis derived from E. coli and S. aureus bacteria — including their superbug forms.

The second patent family is titled “Copolymer for use in a method of treatment of a parenteral infection”. It contains 13 claims and relates to manufacture, administration, and application methods to treat a range of common human infections.

This provides Recce with intellectual property protection until November 2035.

Japan is the second largest pharmaceutical market in the world. Being granted this patent reaffirms RECCE antibiotics’ capability against gram-positive and gram-negative bacteria.

Recce’s main focus is to exploit the capabilities of its RECCE antibiotics to protect against life-threatening bacteria such as Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.

“We are very pleased to continue the expansion of Recce’s Worldwide Patent portfolio. The strength of our patent coverage is yet another step in the commercialisation of RECCE antibiotics across multiple geographic regions,” Recce Chairman Dr John Prendergast said.

This year has been a huge step forward for the company as it has also been granted patents in the U.S. and Europe.

RCE by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).